[{"orgOrder":0,"company":"University of Milan","sponsor":"BMG Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydrogen Peroxide","moa":"PTPN1 messenger RNA (PTPN1 mRNA)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"University of Milan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"University of Milan \/ BMG Pharma","highestDevelopmentStatusID":"10","companyTruncated":"University of Milan \/ BMG Pharma"},{"orgOrder":0,"company":"University of Milan","sponsor":"BMG Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydrogen Peroxide","moa":"PTPN1 messenger RNA (PTPN1 mRNA)","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"University of Milan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"University of Milan \/ BMG Pharma","highestDevelopmentStatusID":"10","companyTruncated":"University of Milan \/ BMG Pharma"},{"orgOrder":0,"company":"University of Milan","sponsor":"Azienda Farmaceutica Italiana","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Polaprezinc","moa":"Tumor necrosis factor; Interleukin-6; Interleukin-3; Vascular endothelial growth factor receptor 1; Beta-nerve growth factor; Platelet-derived growth factor receptor beta; Heat shock protein HSP 90-alpha; Heat shock protein HSP 90-beta","graph1":"Neurology","graph2":"Phase III","graph3":"University of Milan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"University of Milan \/ Azienda Farmaceutica Italiana","highestDevelopmentStatusID":"10","companyTruncated":"University of Milan \/ Azienda Farmaceutica Italiana"}]

Find Clinical Drug Pipeline Developments & Deals by University of Milan

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Hydrogen Peroxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Periodontitis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 25, 2020

                          Lead Product(s) : Hydrogen Peroxide

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase III

                          Sponsor : BMG Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Hydrogen Peroxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Wound Healing.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 18, 2020

                          Lead Product(s) : Hydrogen Peroxide

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase III

                          Sponsor : BMG Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Zinc L-Carnosine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pain.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          June 16, 2020

                          Lead Product(s) : Polaprezinc

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Azienda Farmaceutica Italiana

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Hyaluronic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis, Knee.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 07, 2017

                          Lead Product(s) : Hyaluronic Acid

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase IV

                          Sponsor : Regen Lab

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Tobramycin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cystic Fibrosis.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          May 31, 2012

                          Lead Product(s) : Tobramycin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase IV

                          Sponsor : Chiesi Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank